Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $215M
Founded date: 2020
Investors 4
| Date | Name | Website |
| 01.02.2022 | Vida Ventu... | vidaventur... |
| - | Atlas Vent... | atlasventu... |
| - | NFLS - Piv... | pivotalbio... |
| 20.08.2021 | Lightstone... | lightstone... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.08.2022 | - | $75M | - |
| 18.08.2021 | Series B | $90M | - |
| 17.12.2020 | Series A | $50M | - |
Mentions in press and media 6
| Date | Title | Description |
| 27.06.2024 | Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi | - Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, curren... |
| 16.08.2022 | Vigil Neuroscience Announces $75 Million Private Placement Financing | - |
| 12.08.2022 | Vigil Neuroscience Announces $75 Million Private Placement Financing | CAMBRIDGE, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announ... |
| 18.08.2021 | Vigil Neuroscience Completes $90M Series B | CAMBRIDGE, MA, Vigil Neuroscience, a biotechnology company announced the completion of a $90 million Series B financing led by Vida Ventures. >> Click here for more funding data on Vigil Neuroscience >> To export Vigil Neuro... |
| 08.12.2020 | Vigil Neuroscience Launches $50 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing. Atlas Venture co-found... |
| 08.12.2020 | Neurodegeneration startup launches with $50M, Amgen assets | Eight years after Atlas Venture began probing a group of nervous system cells and their effects in Alzheimer’s and other neurological disorders, the venture creation firm launched a new startup in the field this week. Vigil Neuroscience lau... |